Page 1 | Search Results | Blood | American Society of Hematology

1-16 of 16

Sort by

Sort Order Select

Journal Articles

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL

Rayne Rouce, J. Gregory Dolan, Christine L. Phillips, Muna Qayed, Michael A. Pulsipher, Lauren M. Vernau, Thomas J. Galletta, Sarah Votaw, Gabriela Llaurador Caraballo, Hongbo Yang, Yao Wang, Shashank Ghantoji, Mimi Tesfaye, Soyon Lee, Emer O'Sullivan, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 7724.

https://doi.org/10.1182/blood-2024-203376

Published: 2024

Journal Articles

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Elias Jabbour, David Wei, Hongbo Yang, Kejal Jadhav, Wei Song, Yajin Zhao, Anran Shao, Samantha Tomicki, Daisy Yang, Andrea Damon, Islam Sadek, Vamsi K. Kota

Blood (2024) 144 (Supplement 1): 2434.

https://doi.org/10.1182/blood-2024-201831

Published: 2024

Journal Articles

Maintenance Therapy in Patients with FLT3 -ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Hongbo Yang, Yan Song, James D. Griffin, Manasee V. Shah, Jonathan Freimark, Andrew Chilelli

Blood (2021) 138 (Supplement 1): 693.

https://doi.org/10.1182/blood-2021-145790

Published: 2021

Journal Articles

Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy

Mo Zhou, Hongbo Yang, Yan Song, Deborah A. Marshall, James D. Griffin, Lalit Saini, Manasee V. Shah

Blood (2021) 138 (Supplement 1): 4047.

https://doi.org/10.1182/blood-2021-145385

Published: 2021

Journal Articles

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Hongbo Yang, PhD, Andy Garnham, MSc, Manasee V. Shah, MPH, Amer M. Zeidan, MBBS, MHS

Blood (2020) 136 (Supplement 1): 7.

https://doi.org/10.1182/blood-2020-136184

Published: 2020

Journal Articles

Patient Preferences for Hemophilia a Treatments: A Discrete Choice Experiment

Shawn X. Sun, Jing Zhao, Hongbo Yang, PhD, Eric Wu

Blood (2020) 136 (Supplement 1): 22.

https://doi.org/10.1182/blood-2020-134656

Published: 2020

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Bhavik J. Pandya, PharmD, Cynthia Z. Qi, MBA, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 5085.

https://doi.org/10.1182/blood-2019-123811

Published: 2019

Journal Articles

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Amer M. Zeidan, MBBS, MHS, Cynthia Z. Qi, MBA, Bhavik J. Pandya, PharmD, Andy Garnham, Hongbo Yang, Manasee V Shah, MPH

Blood (2019) 134 (Supplement_1): 3859.

https://doi.org/10.1182/blood-2019-123819

Published: 2019

Journal Articles

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Xinglei Chai, PhD, Cynthia Z. Qi, MBA, Eric Q Wu

Blood (2019) 134 (Supplement_1): 3419.

https://doi.org/10.1182/blood-2019-129070

Published: 2019

Journal Articles

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Hongbo Yang, Yanni Hao, PhD, Cynthia Z. Qi, MBA, Xinglei Chai, PhD, Eric Q Wu

Blood (2019) 134 (Supplement_1): 4723.

https://doi.org/10.1182/blood-2019-129215

Published: 2019

Journal Articles

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

James D. Griffin, MD, Manasee V Shah, MPH, Yan Song, PhD, Hongbo Yang, PhD

Blood (2018) 132 (Supplement 1): 4824.

https://doi.org/10.1182/blood-2018-99-110871

Published: 2018

Journal Articles

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Yanni Hao, PhD, Lamis K. Eldjerou, MD, Hongbo Yang, PhD, Cynthia Qi, MBA, Denise Globe, PhD

Blood (2017) 130 (Supplement 1): 609.

https://doi.org/10.1182/blood.V130.Suppl_1.609.609

Published: 2017

Journal Articles

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

James D. Griffin, MD, Hongbo Yang, PhD, Yan Song, PhD, David Kinrich, BSE, Cat N. Bui, PhD

Blood (2017) 130 (Supplement 1): 2186.

https://doi.org/10.1182/blood.V130.Suppl_1.2186.2186

Published: 2017

Journal Articles

Characterization of Causal Variants at the GATA3 Loci Associated with Susceptibility to Ph-like Acute Lymphoblastic Leukemia

Hui Zhang, PhD MD, Hongbo Yang, PhD, Tingting Liu, PhD, Maoxiang Qian, PhD, Wenjian Yang, PhD, Kathryn G. Roberts, PhD, Virginia Perez-Andreu, MD PhD, Heng Xu, PhD, Julie M. Gastier-Foster, PhD, Colton Smith, PhD, Ching-Hon Pui, MD, William E. Evans, PharmD, Mary V. Relling, PharmD, Stephen P. Hunger, MD, Charles G. Mullighan, MBBS, MD, Mignon L. Loh, MD, Feng Yue, PhD, Jun J. Yang, PhD

Blood (2017) 130 (Supplement 1): 475.

https://doi.org/10.1182/blood.V130.Suppl_1.475.475

Published: 2017

Journal Articles

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

Hongbo Yang, PhD, Anuja Roy, PhD, Chelsey Yang, Evangeline McDonald, Arun Krishna, PhD, Emil T Kuriakose, MD, Denise Globe, PhD, David Siegel, MD PhD, Sundar Jagannath, MD

Blood (2015) 126 (23): 5369.

https://doi.org/10.1182/blood.V126.23.5369.5369

Published: 2015

Journal Articles

An evolutionarily conserved program of B-cell development and activation in zebrafish

Dawne M. Page, Valerie Wittamer, Julien Y. Bertrand, Kanako L. Lewis, David N. Pratt, Noemi Delgado, Sarah E. Schale, Caitlyn McGue, Bradley H. Jacobsen, Alyssa Doty, Yvonne Pao, Hongbo Yang, Neil C. Chi, Brad G. Magor, David Traver

Blood (2013) 122 (8): e1–e11.

https://doi.org/10.1182/blood-2012-12-471029

Published: 2013

Includes: Supplemental data

NARROW

Impact of Current Manufacturing on Kymriah Real-World Effectiveness and Functional Persistence in Acute Lymphoblastic Leukemia (ALL) (KareALL): A Retrospective Study of Tisagenlecleucel (tisa-cel)-Treated Pediatric and Young Adult Patients (pts) with ALL

Adverse Events and Treatment Adjustments Among Newly Diagnosed Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors: A Comprehensive Data Analysis of Medicare Fee-for-Service and Commercial Plans in the United States

Maintenance Therapy in Patients with FLT3 -ITD-Mutation-Positive Acute Myeloid Leukemia after Allogeneic Hematopoietic Cell Transplantation: Real-World Survival

Patient and Physician Preferences for Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Patients Not Candidates for Intensive Chemotherapy

Comparison of Gilteritinib and Salvage Chemotherapy in FLT3 -Mutated Acute Myeloid Leukemia on the Number Needed to Treat for Various Clinical Outcomes: A Secondary Analysis of the Admiral Trial

Patient Preferences for Hemophilia a Treatments: A Discrete Choice Experiment

Cost-Effectiveness Analysis of Gilteritinib Versus Best Supportive Care (BSC) for the Treatment of Relapsed or Refractory (R/R) FLT3 Mutation-Positive ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Cost-Effectiveness Analysis of Gilteritinib Versus Salvage Chemotherapy (SC) for the Treatment of Relapsed or Refractory (R/R) FLT3 -Mutated ( FLT3 mut+ ) Acute Myeloid Leukemia (AML)

Estimation of Total Costs in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Receiving Tisagenlecleucel from a US Hospital's Perspective

Estimation of Total Costs in Pediatric and Young Adult Patients with Relapsed or Refractory Acute Lymphoblastic Leukemia Receiving Tisagenlecleucel from a US Hospital's Perspective

Treatment Patterns and Healthcare Resource Utilization (HRU) in Patients with Relapsed/Refractory (R/R) FLT3 -Mutated ( FLT3 mut ) and FLT3 -Wild Type ( FLT3 wt ) Acute Myeloid Leukemia (AML): A Multi-Country Medical Chart Study

Cost-Effectiveness Analysis of CTL019 for the Treatment of Pediatric and Young Adult Patients with Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia in the United States

Treatment Patterns and Healthcare Resource Utilization in Patients with FLT3-Mut and FLT3-Wt Acute Myeloid Leukemia: A Multi-Country Medical Chart Study

Characterization of Causal Variants at the GATA3 Loci Associated with Susceptibility to Ph-like Acute Lymphoblastic Leukemia

Costs per Month Free of Progression or Death of Targeted Therapies in the Treatment of Relapsed/Refractory Multiple Myeloma

An evolutionarily conserved program of B-cell development and activation in zebrafish

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only